A Phase I Trial to Evaluate the Tolerability, Pharmacokinetics and Preliminary Efficacy of XS-04 in Patients with Hematologic Malignancies
Latest Information Update: 07 Mar 2025
At a glance
- Drugs XS 04 (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
Most Recent Events
- 18 Feb 2025 New trial record